Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
The biotech industry knows that the right biolab and Phase 1 Unit partners are just as vitally important as CRO selection.
In this webinar you will hear from Agilex Biolabs and Phase 1 contract research organisation CMAX about how they work together, and with local and global CROs, to deliver world-class clinical research outcomes.
FDA-inspected Agilex Biolabs is the leading bioanalytical laboratory in Asia Pacific with the most advanced platforms for sensitive technologies, including Gyrolab, to develop state-of-the art assays. Agilex Biolabs has supported hundreds of studies conducted across Australia, Asia Pacific and Europe with the most accurate and quality-controlled bioanalytical services.
Our scientists have a breadth of knowledge and experience in ligand binding assays, antidrug-antibody assays and neutralising antibody assays with in-depth expertise in troubleshooting immunogenicity assays which can often be challenging to develop, to meet the high drug and target tolerance.
CMAX Clinical Research is a leading Phase 1 clinical research organization, literally 10 minutes away from Agilex Biolabs, in South Australia.
CMAX, established in 1993, was the first dedicated early phase research facility in Australia and is one of Australia’s largest and most experienced clinical trial centres. The expert team is committed to supporting innovative medical research in partnership with national and international Sponsors. CMAX is now the Asia Pacific’s ‘go-to’ early phase unit.
This webinar will cover how this this long-standing relationship between Agilex Biolabs and CMAX delivers significant advantages to biotechs wanting a streamlined and collaborative approach to their early phase studies. CMAX also has a Site Management Organisation offering, working with General Practitioners to conduct clinical trials. This offering will be soon branded as Fusion Clinical Research.
Dr Kurt Sales has over 20 years of experience in a career spanning research and development, research management and business development in the UK and South Africa. At Agilex Biolabs, Kurt is responsible for management and oversight of the Agilex Biolabs Immunoassay division.
Kurt has extensive expertise in pre-clinical and clinical assay development, cellular and molecular biology, molecular signaling, flow cytometry, cell-based models and biomarkers, notably in the areas of inflammation and immunology. He also has extensive experience ensuring strict GLP compliance for bioanalytical assays and preclinical safety testing through PK/PD/Biomarker assays.
Widely published with 45 peer-reviewed scientific papers in high impact journals, a book chapter and presentations at over 30 conferences, Kurt also received the prestigious Society for Reproduction and Fertility New Investigator Award.
Kurt has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, and Bachelors of Science in Medicine with Honours in Pharmacology and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organisation and Management and a Post Graduate Certificate in Management.
With a background in nursing and business, Jane was one of the inaugural staff members at CMAX when it was established over 26 years ago and has a long history of leadership within the early phase clinical trials sector.
Working in many positions at CMAX over the years, including business development and project management, Jane has headed up the CMAX business since 2006 and has lead the organisation through many transition periods including the modernisation and expansion of the business to be one of Asia Pacific’s ‘go-to’ early phase units. Established by Faulding Pharmaceuticals in Adelaide, South Australia, CMAX Clinical Research was the first established, dedicated early phase research facility in Australia. CMAX is now fully owned by the I’rom Group, headquartered in Tokyo, and has established a Site Management Organisation in Australia.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.